Patent number: 7476670
Abstract: The invention relates to novel products of formula (I): in which: Y represents N, O, S, CHR3 or ?CR3 the dashed line representing a single or double bond, R and R1 represent in particular H, Hal, OH, alkyl, alkoxy, cyano, NO2, NR4R5, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, —S(O)n-NR4R5 with n representing 0 to 2, acyl, —NH—CO-alkyl or —NH—CO—NH-phenyl, R3 represents H, Hal, alkyl, cyano, NO2, NR4R5, trifluoromethyl or aryl, R2 represents R4, OR4, SR4 or NR4R5, R4 represents H, alkyl, cycloalkyl or aryl, either R4 and R5 are chosen from the values for R4, or R4 and R5 form, with N, a heterocyclic radical which may contain N, O and S, all these radicals being optionally substituted, these products being in all the isomeric forms and the salts, as medicinal products.
Type:
Grant
Filed:
February 17, 2004
Date of Patent:
January 13, 2009
Assignee:
Aventis Pharma S.A.
Inventors:
Florence Bordon-Pallier, Jean-Luc Haesslein
Publication number: 20070185140
Abstract: The invention relates to novel products of formula (I): in which: Y represents N, O, S, CHR3 or ?CR3 the dashed line representing a single or double bond, R and R1 represent in particular H, Hal, OH, alkyl, alkoxy, cyano, NO2, NR4R5, trifluoromethyl, trifluoromethoxy, aryl, heteroaryl, —S(O)n-NR4R5 with n representing 0 to 2, acyl, —NH—CO-alkyl or —NH—CO—NH-phenyl, R3 represents H, Hal, alkyl, cyano, NO2, NR4R5, trifluoromethyl or aryl, R2 represents R4, OR4, SR4 or NR4R5, R4 represents H, alkyl, cycloalkyl or aryl, either R4 and R5 are chosen from the values for R4, or R4 and R5 form, with N, a heterocyclic radical which may contain N, O and S, all these radicals being optionally substituted, these products being in all the isomeric forms and the salts, as medicinal products.
Type:
Application
Filed:
February 17, 2004
Publication date:
August 9, 2007
Applicant:
Aventis Pharma S. A.
Inventors:
Florence Bordon-Pallier, Jean-Luc Haesslein
Patent number: 7041824
Abstract: The use of purine derivatives of formula (I): in which: Rx is —(Z)n—R1 wherein Z is a divalent radical selected from —CH2—, —SO2—, —CO—, —COO—, —CONH— and —(CH2)2—NR6—, n is the an integer selected from 0 and 1, R1 is selected from hydrogen, aryl, —CH2-aryl, —SO2-aryl, heterocyclic, —CH2-heterocyclic, alkyl and —SO2-alkyl, Ry is a phenyl radical (optionally substituted) or the radical: wherein D1 and D2, which are identical or different are selected from hydrogen, hydroxyl, the linear or branched alkyl or alkoxy radicals containing at most 6 carbon atoms and NHR5, or, alternatively, taken together, D1 and D2 form a radical selected from ?O and ?N—OR4, R4 is hydrogen, alkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkyl or aryl, R5 is hydrogen, alkyl, cycloalkyl, or —COOtBu (Boc), and R6 is hydrogen, alkyl or cycloalkyl, wherein the alkyl moiety contains 1 to 6, optionally substituted, carbon atoms; as cdk kinase inhibitors for the prevention and treatment of fungal infections.
Type:
Grant
Filed:
June 26, 2003
Date of Patent:
May 9, 2006
Assignee:
Aventis Pharma S.A.
Inventors:
Florence Bordon-Pallier, Jean-Luc Haesslein